Special Issue

Molecular Mechanisms in Demyelinating Disorders of the Central Nervous System

Message from the Guest Editor

A demyelinating disease is a pathological condition of the nervous system that negatively affects the structure and function of the lipid sheath that surround axons, ultimately interfering with the nerve conduction. These lipid sheaths are lamellar membrane extensions of oligodendrocytes (OLs) in the central nervous system (CNS) and the Schwann cells in the peripheral nervous system (PNS). Myelinoclastic and leukodystrophic are the two categories into which demyelinating diseases have historically been divided.

Among the three main inflammatory-based CNS demyelinating diseases are multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and acute disseminated encephalomyelitis (ADEM). MS is the most prevalent one, affecting millions of people worldwide. Since etiology of these diseases is still largely unknown, there's a need to establish new biomarkers and prioritize the development of experimental research, particularly in the molecular level. I hereby invite authors to submit original research, review articles or commentaries on molecular mechanisms that shed light to therapeutic strategies in demyelinating disorders of the CNS.

Guest Editor

Dr. Paschalis Theotokis

- 1. Laboratory of Experimental Neurology and Neuroimmunology, 2nd Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece
- 2. Laboratory of Histology and Embryology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

Deadline for manuscript submissions

closed (30 September 2023)



Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/129143

Current Issues in Molecular Biology Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 cimb@mdpi.com

mdpi.com/journal/cimb





Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago, Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.

